Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

Abstract

186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) or cyclophosphamide and hexamethylmelamine alternating with doxorubicin and a 5-day course of cisplatin (CHAP-5). Treatment with CHAP-5 resulted in more complete remissions as determined by laparatomy or peritoneoscopy (p = 0.004), better overall response (p = 0.0001), and longer overall survival and progression-free survival (p less than 0.002). Therapy, histological grade, and Karnofsky index were reliable predictors of overall response, whereas therapy, FIGO-stage, and size of residual tumour before chemotherapy were independent predictors for complete remission and for prolonged survival. Peripheral neurotoxicity was a major problem in patients assigned to the CHAP-5-group and was likely to be due to the simultaneous administration of hexamethylmelamine and cisplatin. The CHAP-5 regimen is one of the most effective regimens for the initial treatment of ovarian cancer.

• Authors: J P Neijt, W W ten Bokkel Huinink, M E van der Burg, A T van Oosterom, R Vriesendorp, C D Kooyman, A C van Lindert, J V Hamerlynck, M van Lent, J C van Houwelingen
• Journal: Lancet (London, England) (Lancet) Vol. 2 Issue 8403 Pg. 594-600 (Sep 15 1984) ISSN: 0140-6736 [Print] England
• PMID: 6147640 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Doxorubicin
• Cyclophosphamide
• Cisplatin
• Altretamine
• Fluorouracil
• Methotrexate

Topics

• Altretamine (administration & dosage, adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Cisplatin (administration & dosage, adverse effects)
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage, adverse effects)
• Doxorubicin (administration & dosage, adverse effects)
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Fluorouracil (administration & dosage, adverse effects)
• Humans
• Methotrexate (administration & dosage, adverse effects)
• Ovarian Neoplasms (drug therapy, mortality, surgery)
• Paresthesia (chemically induced)
• Prognosis
• Random Allocation
• Reoperation
• Time Factors